SML4032
CPSF3-IN-1
≥98% (HPLC)
别名:
3-(1,3-Ddihydro-1-hydroxy-2,1-benzoxaborol-7-yl)-N-(40- acetyl-1,10-biphenyl-3-yl) propanamide, N-(4′-Acetyl[1,1′-biphenyl]-3-yl)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole-7-propanamide; benzoxaborole 1
InChI
1S/C24H22BNO4/c1-16(27)17-8-10-18(11-9-17)20-5-3-7-22(14-20)26-23(28)13-12-19-4-2-6-21-15-30-25(29)24(19)21/h2-11,14,29H,12-13,15H2,1H3,(H,26,28)
InChI key
KANKQAZGSKQFCK-UHFFFAOYSA-N
SMILES string
O=C(NC1=CC(C2=CC=C(C=C2)C(C)=O)=CC=C1)CCC3=CC=CC4=C3B(OC4)O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Cell penetrant, potent and selective inhibitor of endonuclease activity of CPSF3 in vitro that limits transcriptional termination in cells.
CPSF3-IN-1 (3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)-N-(40- acetyl-1,10-biphenyl-3-yl) propenamide) is a cell penetrant, potent and selective inhibitor of endonuclease activity of CPSF3 (cleavage and polyadenylation specific factor 3) in vitro that limits transcriptional termination in cells. CPSF3-IN-1 binds to CPSF3 active site and causes transcription readthrough. It potently inhibits growth of numerous cancer cell lines (IC50 = 0.28 µM HCT116 cells).
CPSF3-IN-1 (3-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)-N-(40- acetyl-1,10-biphenyl-3-yl) propenamide) is a cell penetrant, potent and selective inhibitor of endonuclease activity of CPSF3 (cleavage and polyadenylation specific factor 3) in vitro that limits transcriptional termination in cells. CPSF3-IN-1 binds to CPSF3 active site and causes transcription readthrough. It potently inhibits growth of numerous cancer cell lines (IC50 = 0.28 µM HCT116 cells).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Jiong Zhang et al.
Journal of medicinal chemistry, 62(14), 6765-6784 (2019-07-03)
Benzoxaboroles, as a novel class of bioactive molecules with unique physicochemical properties, have been shown to possess excellent antimicrobial activities with tavaborole approved in 2014 as an antifungal drug. Although urgently needed, the investigation of benzoxaboroles as anticancer agents has
Ye Tao et al.
Cell chemical biology, 31(1), 139-149 (2023-11-16)
A novel class of benzoxaboroles was reported to induce cancer cell death but the mechanism was unknown. Using a forward genetics platform, we discovered mutations in cleavage and polyadenylation specific factor 3 (CPSF3) that reduce benzoxaborole binding and confer resistance.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持